Sir.—Ketoconazole is an imidazole-derivative, broad-spectrum antimycotic agent, with relatively limited toxicity compared with other antifungal medications. However, gastrointestinal disturbances, hepatotoxicity, impaired adrenal steroidogenesis, gynecomastia, and immune hemolytic anemia have been reported in association with ketoconazole treatment.1,2 We noticed myopathy with a significant increase of serum creatine phosphokinase during ketoconazole treatment, indicating a possible drug-induced myositis. To our knowledge, there has been no fully documented report of myopathy associated with the use of this drug, although myalgia has been reported in two patients3 and muscular weakness in one patient.4
Patient Report.—A 17-year-old boy afflicted with autoimmune polyglandular syndrome type I presented with hypoparathyroidism, Addison's disease, alopecia universalis, and mucocutaneous candidiasis was treated with ketoconazole (200 mg/d) because of worsening oral candidiasis. Within a week, doctors noticed clinical improvement of the oral lesions, but concomitantly, the patient developed significant weakness and diffuse myalgia, particularly of the shoulder
GARTY B, KAULI R, LIVNI E, LARON Z, NITZAN M. Myopathy Associated With Ketoconazole Treatment. Am J Dis Child. 1991;145(9):970–971. doi:10.1001/archpedi.1991.02160090020010
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: